The Efficacy of Intraluminal Brachytherapy as Palliative Therapy of Hilar Cholangiocarcinoma.
10.15279/kpba.2015.20.2.71
- Author:
Jin Seok PARK
1
;
Seok JEONG
;
Woo Chul KIM
;
Don Haeng LEE
Author Information
1. Digestive Disease Center, Department of Internal Medicine, Inha University School of Medicine, Incheon, Korea. inos@inha.ac.kr
- Publication Type:Original Article
- Keywords:
Cholangiocarcinoma;
Radiotherapy;
Stents;
Radiation dosage;
Survival analysis
- MeSH:
Brachytherapy*;
Cholangiocarcinoma*;
Humans;
Palliative Care*;
Radiation Dosage;
Radiotherapy;
Stents;
Survival Analysis
- From:Korean Journal of Pancreas and Biliary Tract
2015;20(2):71-77
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The aim of this study is to assess the therapeutic benefits of a combination of external beam radiation therapy (EBRT) and intraluminal brachytherapy (ILBT) in hilar cholangiocarcinoma as palliative therapy. METHODS: A total of 21 patients with hilar cholangiocarcinoma were included. Only 12 patients were treated with EBRT (group 1), and only nine patients were treated with EBRT and ILBT (group 2). The survival data and stent patency period were measured in both groups and the results were compared. RESULTS: No statistically significant difference in patient survival was observed between the two groups. The median survival period of group 1 was 353 days and that of group 2 was 224 days. Also, stent patency did not differ significantly between groups. The period for group 1 was 250 days, and that of group 2 was 133 days. In addition, there were no other factors influencing patient survival and stent patency period. However, patient survival tended to increase with increase in the amount of irradiation dose (Spearman's correlation coefficient=0.65, p=0.065). CONCLUSIONS: EBRT with ILBT did not have a benefit when compared with the treatment effect of EBRT alone as palliative therapy for hilar cholangiocarcinoma.
